Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
Twist will leverage C2i’s leadership in whole-genome cancer signatures across solid cancers to generate unique synthetic reference materials for cancer detection validation in labs across the globe
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
The platform’s technology works as a compression algorithm for molecular testing
Cryo-technology helps in early diagnosis and palliative care in later stages of cancer
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
Expertise in exosomes isolation and characterization will drive innovation in this field
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
Subscribe To Our Newsletter & Stay Updated
